Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring
Posted inCardiology General Surgery news

Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring

The DALI cohort study reveals that while current DOAC interruption protocols are generally effective, 13.1% of apixaban users maintain levels ≥30 ng/mL before surgery. However, these residual levels did not correlate with increased surgical blood loss, suggesting other factors drive perioperative bleeding.
Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation
Posted innews Psychiatry

Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation

A comprehensive meta-analysis in JAMA Psychiatry reveals that current psychosocial interventions for schizophrenia and co-occurring substance use disorders offer negligible impact on symptoms and no significant effect on substance use reduction, with the notable exception of nicotine cessation strategies.
Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
Posted inCardiology Hematology-Oncology news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer alternative for high-risk geriatric populations.